Print Get Citation Citation AMA Citation Chan A, Shah R. Chan A, Shah R Chan, Alex, and Ravi Shah. "Improved SARS-CoV-2 clearance with combination hydroxychloroquine and azithromycin." 2 Minute Medicine, 27 March 2020. McGraw-Hill, New York, NY, 2020. AccessPediatrics. http://accesspediatrics.mhmedical.com/updatesContent.aspx?gbosid=541704§ionid=243121585 MLA Citation Chan A, Shah R. Chan A, Shah R Chan, Alex, and Ravi Shah.. "Improved SARS-CoV-2 clearance with combination hydroxychloroquine and azithromycin." 2 Minute Medicine New York, NY: McGraw-Hill, 2020, http://accesspediatrics.mhmedical.com/updatesContent.aspx?gbosid=541704§ionid=243121585. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Improved SARS-CoV-2 clearance with combination hydroxychloroquine and azithromycin by Alex Chan, Ravi Shah Listen +Originally published by 2 Minute Medicine® (view original article). Reused on AccessMedicine with permission. +1. Hydroxychloroquine treatment was found to significantly reduce viral load in COVID-19 patients, and had an enhanced effect when azithromycin was included in treatment +Evidence Rating: 2 (Good) +Despite significant research efforts, there currently exists no approved pharmacolgic therapy for the direct treatment of COVID-19 to reduce viral load. Significant effort has been placed on the repositioning of old drugs for treatment of COVID-19 as they have known safety profiles, side effects, and interactions. Chloroquine, an old antimalarial drug, has been one drug evaluated for this purpose as prior literature has demonstrated anti-SARS-CoV activity in vitro and ability to reduce viral load in an early clinical trial. To expand upon study findings, researchers conducted an open-label non-randomized clinical trial enrolling 42 hospitalized patients with laboratory confirmed COVID-19. Twenty-six patients were assigned to receive 200mg of hydroxychloroquine, a safer analogue of chloroquine, three times daily for ten days, 6 of whom additionally received azithromycin (500mg on day 1 followed by 250mg daily for 4 the next days). At day 6 post inclusion, nasopharyngeal samples demonstrated that 100% of the combinational therapy group had virological clearance, compared to 57.1% in the hydroxychloroquine only group, and 12.5% in the controls. Hydroxychloroquine therapy (with azithromycin or alone) was found to be significantly associated with greater viral load reduction when compared to controls (p=0.001), and combinational therapy with azithromycin was found to be significantly more effective than hydroxychloroquine alone (p<0.001). Despite a small sample size and relative short follow-up, study findings are promising in demonstrating that hydroxychloroquine with azithromycin may be used as a therapeutic option for hospitalized COVID-19 patients. Additional study is required to assess correlation to clinical outcomes as well as safety and efficacy across a larger sample size. +Click to read the study in the International Journal of Antimicrobial Agents +©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.